Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria

Publication Type:

Journal Article

Source:

Head & neck, Volume 32, Issue 2, p.221-8 (2010)

Keywords:

Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Cisplatin, Disease-Free Survival, Dose Fractionation, Female, Fluorouracil, Head and Neck Neoplasms, Humans, Male, Middle Aged, Radiotherapy, Adjuvant, Taxoids

Abstract:

In an effort to optimize nonoperative therapy in patients with locoregionally advanced head and neck squamous cell cancer, the Southwest Oncology Group conducted a phase II trial combining 3-drug taxane-containing induction chemotherapy with accelerated fractionation/concomitant boost radiation and concomitant single-agent cisplatin.